Df Dent & Co Inc increased Lowe’s Companies Inc (LOW) stake by 10.67% reported in 2018Q4 SEC filing. Df Dent & Co Inc acquired 3,458 shares as Lowe’s Companies Inc (LOW)’s stock rose 10.14%. The Df Dent & Co Inc holds 35,877 shares with $3.31 million value, up from 32,419 last quarter. Lowe’s Companies Inc now has $92.32 billion valuation. The stock increased 0.75% or $0.86 during the last trading session, reaching $115.99. About 1.76M shares traded. Lowe’s Companies, Inc. (NYSE:LOW) has risen 17.31% since April 12, 2018 and is uptrending. It has outperformed by 12.94% the S&P500. Some Historical LOW News: 26/03/2018 – Lowe’s: Board Initiates Search for Successor to CEO Niblock; 23/05/2018 – RBA’S LOWE: HAVE MORE STAFF LOOKING AT CHINA THAN ANY OTHER SINGLE OVERSEAS ECONOMY; 23/05/2018 – Lowe’s sticks to annual forecasts, expects sales rebound; 05/03/2018 – RBA’s Lowe Keeps Benchmark Interest Rate at 1.5% (Full Text); 23/05/2018 – Lowe’s Has Market Value of About $77.7 Billion; 18/03/2018 – Weijia Jiang, Luther Lowe; 11/04/2018 – RBA Gov Lowe: Australian Economy Making Progress Toward Higher Growth; 23/05/2018 – LOWE’S COMPANIES INC -; 15/05/2018 – Glenhill Adds Arris, Exits Lowe’s, Cuts Lennar: 13F; 08/05/2018 – ENERCARE NAMES GEOFF LOWE AS CFO
The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 3.04% or $1.43 during the last trading session, reaching $48.5. About 172,907 shares traded or 7.11% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 12, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating ResultsThe move comes after 9 months positive chart setup for the $1.26 billion company. It was reported on Apr, 12 by Barchart.com. We have $52.87 PT which if reached, will make NASDAQ:IFRX worth $113.31 million more.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Benzinga.com which released: “38 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” on April 09, 2019, also Benzinga.com with their article: “46 Biggest Movers From Yesterday – Benzinga” published on April 10, 2019, Seekingalpha.com published: “InflaRx down 14% – Seeking Alpha” on November 19, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results – GlobeNewswire” published on November 21, 2018 as well as Globenewswire.com‘s news article titled: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” with publication date: February 14, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.26 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Since November 23, 2018, it had 1 buy, and 0 sales for $880,200 activity. 10,000 shares were bought by ROGERS BRIAN C, worth $880,200.
Among 18 analysts covering Lowe’s Companies (NYSE:LOW), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Lowe’s Companies had 30 analyst reports since October 15, 2018 according to SRatingsIntel. As per Tuesday, March 19, the company rating was maintained by Morgan Stanley. The firm has “Hold” rating by Loop Capital given on Wednesday, January 23. The stock has “Neutral” rating by Credit Suisse on Wednesday, October 17. The stock of Lowe’s Companies, Inc. (NYSE:LOW) has “Buy” rating given on Thursday, February 28 by Raymond James. PiperJaffray maintained it with “Neutral” rating and $93 target in Wednesday, November 21 report. Oppenheimer maintained it with “Buy” rating and $125 target in Wednesday, February 27 report. The firm has “Hold” rating by Gordon Haskett given on Thursday, November 8. As per Wednesday, November 21, the company rating was maintained by KeyBanc Capital Markets. Morgan Stanley maintained the stock with “Overweight” rating in Thursday, February 28 report. The stock of Lowe’s Companies, Inc. (NYSE:LOW) has “Buy” rating given on Tuesday, October 23 by Citigroup.
More important recent Lowe’s Companies, Inc. (NYSE:LOW) news were published by: Seekingalpha.com which released: “How Safe Is Lowe’s Dividend? – Seeking Alpha” on March 21, 2019, also Seekingalpha.com published article titled: “Moody’s expects margin improvement from Lowe’s – Seeking Alpha”, Fool.com published: “3 Great Stocks for Low-Risk Investors – The Motley Fool” on April 08, 2019. More interesting news about Lowe’s Companies, Inc. (NYSE:LOW) was released by: Seekingalpha.com and their article: “Callon Petroleum’s Asset Sale Was An Excellent Move – Seeking Alpha” with publication date: April 12, 2019.
Df Dent & Co Inc decreased United Technologies Corp. (NYSE:UTX) stake by 7,398 shares to 23,458 valued at $2.50M in 2018Q4. It also reduced Exponent Inc (NASDAQ:EXPO) stake by 28,378 shares and now owns 33,334 shares. Blackbaud Inc (NASDAQ:BLKB) was reduced too.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.